Study Details
Testing the Drug CAL101 for People with Idiopathic Pulmonary Fibrosis
(IRB#: IRB_00189965)
Idiopathic Pulmonary Fibrosis is a chronic lung disease causing thickening and scarring of lung tissue, making it difficult to breathe. This study will test a drug called CAL101 to treat people with this disease. The study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen to be treated with CAL101 or a placebo. A placebo looks like the study drug but does not have the medication. Being in the study requires 10 study visits at the clinic over about 40 weeks. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 40 years and older
- Diagnosis of Idiopathic Pulmonary Fibrosis
- On a stable dose of nintedanib or pirfenidone treatment for 8 weeks or no treatment with nintedanib or pirfenidone for at 8 least weeks before study participation
- Must use specific birth control during the study and for 6 months after the last dose of study medication
- Able to attend in person visits at the study clinic
Exclusion Criteria
- Any other serious lung disease, such as asthma, chronic obstructive pulmonary disease, cavitary, or pleural diseases
- Interstitial lung disease other than Idiopathic Pulmonary Fibrosis
- Pregnant or breastfeeding
- Current smoker or vaper
- Major surgery within 3 months before study participation or planned during the study (being on a transplant list is allowed)
Will I be paid for my time?
Yes
IRB#: IRB_00189965
PI: Mary Beth Scholand
Department: PULMONARY
Approval Date: 2025-08-27 06:00:00
Specialties: Pulmonary
I am Interested